Advanced Search
MyIDEAS: Login

Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France

Contents:

Author Info

  • Xavier Colin

    (Cemka-Eval, 43 Boulevard du Marchal Joffre, 92340 Bourg-la-Reine, France)

  • Antoine Lafuma

    (Cemka-Eval, 43 Boulevard du Marchal Joffre, 92340 Bourg-la-Reine, France)

  • Dominique Costagliola

    (INSERM, Unit Mixte de Recherche (UMR) S 720, and Universit Pierre et Marie Curie-Paris 6, UMR S 720, Paris, France)

  • Erik Smets

    (Johnson Johnson Pharmaceutical Services LLC, Mechelen, Belgium)

  • Josephine Mauskopf

    (RTI HEALTH Solutions, Research Triangle Park, North Carolina, USA)

  • Pascal Guillon

    (Janssen Cilag SAS, Issy les Moulineaux, France)

Registered author(s):

    Abstract

    Background: A key element for payers in the assessment of the economic profile of a medication is its anticipated impact on the evolution of healthcare budgets. Objectives: To forecast the impact of the use of darunavir with low-dose ritonavir 600/100 mg twice a day (bid) in highly treatment-experienced, HIV-infected adults who have failed one or more protease inhibitor (PI)-containing regimen on the budget of the French Sickness Fund (French healthcare system) over a 3-year time horizon. Methods: A transition state model based on disease severity was developed that compared the evolution of antiretroviral and non-antiretroviral-related direct costs of care in the target population over 3 years (2007-2009) under two scenarios: (1) darunavir enters the French market in year 1; (2) darunavir is not available to the target population during 2007-2009. Model inputs were derived from a targeted analysis of the French hospital database in HIV, the darunavir POWER 1 and 2 trials and other relevant clinical studies. Results: In the scenario where darunavir was available from year 1, the proportion of patients in the lower, more costly CD4 cell count strata (≤100 cells per mm) was consistently lower than in the scenario without darunavir in each year of the model (17.0% vs 19.2%, 13.9% vs 18.3% and 10.8% vs 16.8% for years 1, 2 and 3, respectively). As a result, over the entire 3-year period, the net increase of antiretroviral drug costs (+5.6 million Euros; &U20AC;), resulting from the substitution of older, cheaper PIs by darunavir, is expected to be fully compensated by savings in hospitalization costs (&U20AC;-9.7 million) and expenditures for other HIV-related (non-antiretroviral) medications (&U20AC;-7.3 million), leading to a net saving of &U20AC;11.4 million or 2.9% of the total budget in the scenario without darunavir. Various sensitivity analyses confirmed these projected savings. Conclusion: The use of darunavir/ritonavir (DRV/r) 600/100 mg bid, in combination with other antiretroviral agents, in highly pre-treated, HIV-infected adults who have failed one or more PI-containing highly active antiretroviral therapy regimen is not expected to increase the budget of the French healthcare system, in comparison with a scenario without darunavir. Further research is needed to estimate the budget impact of the use of DRV/r in less treatment-experienced, HIV-infected individuals in France.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201028001-00014.pdf
    Download Restriction: Pay per view

    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/fulltext.00019053-201028001-00014.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 28 (2010)
    Issue (Month): S1 ()
    Pages: 183-197

    as in new window
    Handle: RePEc:wkh:phecon:v:28:y:2010:i:s1:p:183-197

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    Related research

    Keywords: Antiretrovirals; therapeutic use; Budget-impact-analysis; Darunavir; therapeutic use; HIV-infections; treatment; Peptide-hydrolase-inhibitors; therapeutic use; Ritonavir; therapeutic use;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:28:y:2010:i:s1:p:183-197. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.